ArticlePharmacoEconomics2014

Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.

Torbjørn Wisløff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.